Clinical Scorecard: PRISM Trial Update Presented at RWC
At a Glance
| Category | Detail |
|---|---|
| Condition | Wet Age-related Macular Degeneration (AMD) |
| Key Mechanisms | Intravitreal delivery of aflibercept and inhibitory RNA targeting VEGF-C |
| Target Population | Patients with wet AMD, particularly those recently diagnosed |
| Care Setting | Ophthalmology clinics |
Key Highlights
- 4D-150 showed expression of aflibercept for up to 104 weeks.
- 57% of patients were injection-free at 52 weeks.
- 80% injection-free rate in patients diagnosed 6 months or sooner.
- Safety profile indicated 2.8% experienced transient cell issues, well tolerated.
- 99% completed steroid taper on time.
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and OCT findings for wet AMD.
Management
- Consider 4D-150 for patients needing reduced anti-VEGF treatment frequency.
Monitoring & Follow-up
- Monitor visual acuity and OCT findings regularly post-treatment.
Risks
- Monitor for transient cell issues and manage steroid taper.
Patient & Prescribing Data
Patients with wet AMD, especially those recently diagnosed.
4D-150 may reduce the need for frequent anti-VEGF injections.
Clinical Best Practices
- Incorporate patient education on the treatment regimen and potential side effects.
- Ensure regular follow-up for monitoring treatment efficacy and safety.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
